- Trials with a EudraCT protocol (246)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18)
246 result(s) found for: Haemophilia.
Displaying page 1 of 13.
EudraCT Number: 2018-004891-36 | Sponsor Protocol Number: NN7415-4307 | Start Date*: 2019-11-20 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Temporarily Halted) GB (GB - no longer in EU/EEA) FR (Ongoing) PT (Trial now transitioned) HR (Ongoing) HU (Ongoing) LT (Trial now transitioned) EE (Ongoing) IT (Restarted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002641-37 | Sponsor Protocol Number: NN7415-4580 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||||||||||||
Full Title: Efficacy and safety of once-weekly subcutaneous administration of concizumab prophylaxis in patients with haemophilia A and B, with or without inhibitors | ||||||||||||||||||||||||||||
Medical condition: Haemophilia A Haemophilia A with inhibitors Haemophilia B Haemophilia B with inhibitors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001048-24 | Sponsor Protocol Number: NN7769-4514 | Start Date*: 2021-05-18 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors. | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia A with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Ongoing) SK (Ongoing) DK (Ongoing) DE (Ongoing) BE (Completed) AT (Ongoing) LV (Ongoing) LT (Ongoing) NL (Ongoing) PL (Ongoing) PT (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000510-30 | Sponsor Protocol Number: NN7415-4310 | Start Date*: 2017-06-08 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A with inhibitors Haemophilia B with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: SE (Completed) DK (Completed) GB (Completed) GR (Prematurely Ended) ES (Completed) AT (Completed) HR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016383-36 | Sponsor Protocol Number: NN7008-3545 | Start Date*: 2010-06-15 | |||||||||||
Sponsor Name:NOVO NORDISK | |||||||||||||
Full Title: A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A | |||||||||||||
Medical condition: Following EMEA guidelines NN7008-3545 trial is a prospective clinical phase 3a trial intended at demonstrating safety and efficacy of N8 in previously treated patients < 12 years of age with severe... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003467-26 | Sponsor Protocol Number: NN7769-4516 | Start Date*: 2021-11-30 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia A with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000614-29 | Sponsor Protocol Number: NN7415-4255 | Start Date*: 2017-06-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without Inhibitors | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Temporarily Halted) DE (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002396-99 | Sponsor Protocol Number: NN7170-4213 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BG (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004889-34 | Sponsor Protocol Number: NN7415-4311 | Start Date*: 2019-10-07 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A with inhibitors Haemophilia B with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) AT (Completed) FR (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SK (Completed) NO (Ongoing) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) HR (Ongoing) IT (Restarted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003960-20 | Sponsor Protocol Number: NN7008-3543 | Start Date*: 2009-06-26 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy ... | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003027-61 | Sponsor Protocol Number: B1821048 | Start Date*: 2015-12-23 |
Sponsor Name:Pfizer Inc. | ||
Full Title: An open-label, single dose pharmacokinetic study of BeneFIX (nonacog alfa, recombinant factor IX) in male Chinese subjects with haemophilia B. | ||
Medical condition: Haemophilia B | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-023242-69 | Sponsor Protocol Number: GENA-11 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study to Investigate the Long-Term Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients with Severe Haemophilia A – Extension Study to GENA-01 | |||||||||||||
Medical condition: Severe haemophilia A (FVIII:C <1%) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003788-36 | Sponsor Protocol Number: NN7088-4410 | Start Date*: 2018-03-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: LT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) GR (Completed) NO (Completed) DK (Completed) HU (Completed) FR (Completed) NL (Completed) DE (Completed) ES (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001142-15 | Sponsor Protocol Number: NN7088-3859 | Start Date*: 2012-05-14 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 (N8-GP) when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemoph... | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) NO (Completed) DK (Completed) ES (Completed) GB (Completed) HU (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023803-92 | Sponsor Protocol Number: NN1731-3562 | Start Date*: 2011-06-01 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors | ||||||||||||||||||
Medical condition: Congenital Haemophilia and Inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (Completed) AT (Completed) GR (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000504-11 | Sponsor Protocol Number: NN7415-4616 | Start Date*: 2022-04-05 | ||||||||||||||||||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | ||||||||||||||||||||||||||||
Full Title: Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors | ||||||||||||||||||||||||||||
Medical condition: Haemophilia A with or without inhibitors Haemophilia B with our without inhibitors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) NO (Ongoing) GR (Ongoing) SE (Ongoing) LT (Ongoing) EE (Ongoing) BG (Ongoing) PL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001033-16 | Sponsor Protocol Number: NN7008-3809 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) AT (Completed) ES (Completed) GR (Completed) DK (Completed) HU (Completed) LT (Completed) PL (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004025-88 | Sponsor Protocol Number: NN7088-3908 | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A An open-label single-arm multicentre non-controlled phase 3a trial investigating safety a... | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Temporarily Halted) PT (Ongoing) GR (Completed) BG (Completed) RO (Ongoing) IT (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001104-23 | Sponsor Protocol Number: CSLCT-BIO-07-47 | Start Date*: 2009-01-22 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase II, multicentre, double-blinded, randomised, cross-over study to evaluate efficacy, safety and pharmacokinetics of Biostate® in subjects with Haemophilia A. | |||||||||||||
Medical condition: Haemophilia A - a hereditary bleeding disorder characterised by a deficiency in the plasma protein known as coagulation Factor VIII (FVIII). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002510-50 | Sponsor Protocol Number: Biostate_4001 | Start Date*: 2018-03-19 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.